We are live on ! Find out more
GALT icon

Galectin Therapeutics

55 hedge funds and large institutions have $15.2M invested in Galectin Therapeutics in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more call options, than puts

Call options by funds: $759K | Put options by funds: $348K

27% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 11

0.05% more ownership

Funds ownership: 12.29% → 12.35% (+0.05%)

7% less capital inflows, than outflows

Capital inflows: $1.57M | Capital outflows: $1.69M

21% less funds holding

Funds holding: 70 → 55 (-15)

74% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 19

Holders
55
Holders Change
-15
Holders Change %
-21.43%
% of All Funds
0.84%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
14
Reduced
11
Closed
19
Calls
$759​K
Puts
$348​K
Net Calls
+$411​K
Net Calls Change
-⁠$1.2​M

GALT Hedge Fund Activity: Q4 2021 in Review

55 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2021, worth a combined $15.2M — down 46% from $28.2M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of GALT and 5 opened new positions — a net loss of 14 holders — while 11 trimmed existing stakes and 14 added.

The largest buyer was Renaissance Technologies, adding an estimated $586K. The largest seller was Ergoteles, exiting entirely with an estimated $529K sold.

  • 55 institutional investors held Galectin Therapeutics (GALT) as of Q4 2021, down from 70 in Q3 2021.
  • Funds reported $15.2M of Galectin Therapeutics stock for Q4 2021, down 46% quarter-over-quarter.
  • 5 funds opened new Galectin Therapeutics positions in Q4 2021 and 19 closed out, a net change of -14 holders.
  • The largest Galectin Therapeutics buyer in Q4 2021 was Renaissance Technologies, an estimated $586K added.
  • The largest Galectin Therapeutics seller in Q4 2021 was Ergoteles, an estimated $529K sold.

Based on aggregated 13F filings for Q4 2021.